TY - JOUR
T1 - Intragenic amplification of PAX5
T2 - a novel subgroup in B-cell precursor acute lymphoblastic leukemia?
AU - Schwab, Claire
AU - Nebral, Karin
AU - Chilton, Lucy
AU - Leschi, Cristina
AU - Waanders, Esmé
AU - Boer, Judith M
AU - Žaliová, Markéta
AU - Sutton, Rosemary
AU - Öfverholm, Ingegerd Ivanov
AU - Ohki, Kentaro
AU - Yamashita, Yuka
AU - Groeneveld-Krentz, Stefanie
AU - Froňková, Eva
AU - Bakkus, Marleen
AU - Tchinda, Joelle
AU - Barbosa, Thayana da Conceição
AU - Fazio, Grazia
AU - Mlynarski, Wojciech
AU - Pastorczak, Agata
AU - Cazzaniga, Giovanni
AU - Pombo-de-Oliveira, Maria S
AU - Trka, Jan
AU - Kirschner-Schwabe, Renate
AU - Imamura, Toshihiko
AU - Barbany, Gisela
AU - Stanulla, Martin
AU - Attarbaschi, Andishe
AU - Panzer-Grümayer, Renate
AU - Kuiper, Roland P
AU - den Boer, Monique L
AU - Cavé, Hélène
AU - Moorman, Anthony V
AU - Harrison, Christine J
AU - Strehl, Sabine
N1 - Funding Information:
This work was supported by Bloodwise (formerly Leukaemia and Lymphoma Research) and the Anniversary Fund of the Austrian National Bank (OeNB grant 14133) (K.N.). M.Z., E.F., and J. Trka are supported by NV15-30626A and 00064203 (FN Motol). E.W. is supported by the Dutch Cancer Society (KUN2012-5366). R.S. is supported by National Health and Medical Research Council Australia (APP1057746). M.L.d.B. and J.M.B. are supported by the KiKa Foundation (Kinderen Kankervrij) and the European Union's Seventh Framework Program (FP7/2007-2013) under the project European Network for Cancer Research in Children and Adolescents (ENCCA; grant agreement HEALTH-F2-2011-261474). A.P. was supported by the National Center of Research and Development (LIDER grant 031/635/l-5/13/NCBR/2014). H.C. and C.L. were supported by the European Commission Seventh Framework Programme (FP7) ERA-NET on Translational Cancer Research (TRANSCAN) project TRANSCALL. R.K.-S. is supported by the German Childhood Cancer Foundation (grant DKS 2011.14). G.C. and G.F. are supported by the Italian Association for Cancer Research (AIRC).
Funding Information:
This work was supported by Bloodwise (formerly Leukaemia and Lymphoma Research) and the Anniversary Fund of the Austrian National Bank (OeNB grant 14133) (K.N.). M.Z., E.F., and J. Trka are supported by NV15-30626A and 00064203 (FN Motol). E.W. is supported by the Dutch Cancer Society (KUN2012-5366). R.S. is supported by National Health and Medical Research Council Australia (APP1057746). M.L.d.B. and J.M.B. are supported by the KiKa Foundation (Kinderen Kankervrij) and the European Union’s Seventh Framework Program (FP7/2007-2013) under the project European Network for Cancer Research in Children and Adolescents (ENCCA; grant agreement HEALTH-F2-2011-261474). A.P. was supported by the National Center of Research and Development (LIDER grant 031/635/l-5/13/NCBR/2014). H.C. and C.L. were supported by the European Commission Seventh Framework Programme (FP7) ERA-NET on Translational Cancer Research (TRANSCAN) project TRANSCALL. R.K.-S. is supported by the German Childhood Cancer Foundation (grant DKS 2011.14). G.C. and G.F. are supported by the Italian Association for Cancer Research (AIRC).
PY - 2017/8/22
Y1 - 2017/8/22
N2 - Intragenic PAX5 amplification defines a novel, relapse-prone subtype of B-cell precursor acute lymphoblastic leukemia with a poor outcome.
AB - Intragenic PAX5 amplification defines a novel, relapse-prone subtype of B-cell precursor acute lymphoblastic leukemia with a poor outcome.
UR - https://www.scopus.com/pages/publications/85058812828
U2 - 10.1182/bloodadvances.2017006734
DO - 10.1182/bloodadvances.2017006734
M3 - Article
C2 - 29296789
SN - 2473-9529
VL - 1
SP - 1473
EP - 1477
JO - Blood advances
JF - Blood advances
IS - 19
ER -